NanoRepro AGHAM:NN6 -2.12%51 EBIT per Share is €-0.17 as of Jun. 2025. GuruFocus rates HAM:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 598801.8% on this metric.
NanoRepro AG's EBIT per Share for the
six
months ended in Jun. 2025 was €-0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.17.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NanoRepro AG's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NanoRepro AG was 75.80% per year. The lowest was -59.90% per year. And the median was 14.85% per year.
HAM:NN6's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.2 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
NanoRepro AG's EBIT for the
six
months ended in Jun. 2025 was €-0.90 Mil.
NanoRepro AG (HAM:NN6) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NanoRepro AG EBIT per Share Related Terms
NanoRepro AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (HAM:NN6) has a EBIT per Share of €-0.17 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry.
Is NanoRepro AG's EBIT per Share too high?
NanoRepro AG's current EBIT per Share is €-0.17. Based on the distribution chart, NanoRepro AG ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #999999 out of 167 companies for EBIT per Share. This places NanoRepro AG in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current EBIT per Share is €-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (HAM:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.05, compared to a current price of €2.31 — trading 120% above its estimated fair value. The current EBIT per Share is €-0.17. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NanoRepro AG (HAM:NN6), the current EBIT per Share is €-0.17 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (HAM:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.31 is trading 120% above its estimated GF Value™ of €1.05.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for HAM:NN6:
EBIT per Share: €-0.17
GF Value™: €1.05 vs. price of €2.31 (120% above fair value)
No single metric tells the full story. See the HAM:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for HAM:NN6
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NN6 has been successfully added to your 
